ASH 2015 - Orlando - CML - Chronic Myeloid Leukemia
CML Program
Saturday, December 5, 2015
Managing Typical and Atypical Chronic Myeloid Leukemia
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: CML – Mechanisms of Disease Progression and Leukemic Stem Cell Persistence
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster I
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia
632. Chronic Myeloid Leukemia: Therapy: Poster I
632. Chronic Myeloid Leukemia: Therapy Program: Oral and Poster Abstracts Type: Poster
632. Chronic Myeloid Leukemia: Therapy: Clinical Trials, Observations, and Molecular Monitoring
Sunday, December 6, 2015
632. Chronic Myeloid Leukemia: Therapy: Treatment-Free Remission, Mutations, and Prognosis
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II
632. Chronic Myeloid Leukemia: Therapy: Poster II
Monday, December 7, 2015
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III
632. Chronic Myeloid Leukemia: Therapy: Poster III
632. Chronic Myeloid Leukemia: Therapy: Clinical and Molecular Predictors of Outcomes and Toxicities
632. Chronic Myeloid Leukemia: Therapy and Prognosis
Forums and Patient associations 'reports
iCMLf Forum during ASH on December 4, 2015:Case discussions on CML management for physicians from Emerging Economic Regions
Abstracts and notes on CML presentations at ASH 2015. Orlando
By Steve O’Brien, Newcastle University
NEWS
First-line dasatinib plus pegylated-interferon alpha 2b induces deep molecular responses in CML
December 7, 2015, Healio
In CP-CML, Deep Molecular Responses to TKIs Result from Immune Suppressor Activity
December 5, 2015, OncologyNurseAdvisor
VIDEO
CML Takeaways From ASH 2015: Discontinuing Tyrosine Kinase Inhibitors
December 22, 2015, Medscape Oncology
SOME INTERESTING ABSTRACTS FOR CML
Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients
Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis
ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy
Bull's-Eyes and Blind Spots: Pre-Clinical Studies with the Allosteric Inhibitor ABL001 in BCR-ABL1 Compound Mutation-Based Resistance
Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients
Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study
Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission
Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase
Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience
Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia
Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial
Inecalcitol, a Novel Adjuvant Therapy Inhibiting Chronic Myeloid Leukemia (CML) Stem Cells, Activates a Macrophage Differentiation Pathway in Leukemic Progenitors
The Long Non-Coding RNA NEAT1 Modulates Imatinib-Induced Apoptosis in CML Cells
Pulmonary Complications in Patients Treated with Tyrosine Kinase Inhibitors, a Systematic Review and Meta-Analysis
Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias
Switching to Nilotinib Are Associated with Deeper Molecular Responses in Chronic Myeloid Leukemia with Persistent Residual Disease on Long-Term Imatinib Therapy: STAT1 Trial in Japan
Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?
Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study
Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study
Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib
Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients
Velocity of Early BCR-ABL Transcript Elimination As an Optimized Predictor of Deep Molecular Response in Chronic Myeloid Leukemia Patients in Chronic Phase on Treatment with Dasatinib
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib
Interim Analysis of a Multicenter, Prospective Study for Pediatric Chronic Myeloid Leukemia in Chronic Phase: The JPLSG CML-08 Study
Description and Management of Accelerated Phase and Blast Crisis in 21 CML Pediatric Patients
Saturday, December 5, 2015
Managing Typical and Atypical Chronic Myeloid Leukemia
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: CML – Mechanisms of Disease Progression and Leukemic Stem Cell Persistence
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster I
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia
632. Chronic Myeloid Leukemia: Therapy: Poster I
632. Chronic Myeloid Leukemia: Therapy Program: Oral and Poster Abstracts Type: Poster
632. Chronic Myeloid Leukemia: Therapy: Clinical Trials, Observations, and Molecular Monitoring
Sunday, December 6, 2015
632. Chronic Myeloid Leukemia: Therapy: Treatment-Free Remission, Mutations, and Prognosis
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II
632. Chronic Myeloid Leukemia: Therapy: Poster II
Monday, December 7, 2015
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III
632. Chronic Myeloid Leukemia: Therapy: Poster III
632. Chronic Myeloid Leukemia: Therapy: Clinical and Molecular Predictors of Outcomes and Toxicities
632. Chronic Myeloid Leukemia: Therapy and Prognosis
Forums and Patient associations 'reports
iCMLf Forum during ASH on December 4, 2015:Case discussions on CML management for physicians from Emerging Economic Regions
Abstracts and notes on CML presentations at ASH 2015. Orlando
By Steve O’Brien, Newcastle University
NEWS
First-line dasatinib plus pegylated-interferon alpha 2b induces deep molecular responses in CML
December 7, 2015, Healio
In CP-CML, Deep Molecular Responses to TKIs Result from Immune Suppressor Activity
December 5, 2015, OncologyNurseAdvisor
VIDEO
CML Takeaways From ASH 2015: Discontinuing Tyrosine Kinase Inhibitors
December 22, 2015, Medscape Oncology
SOME INTERESTING ABSTRACTS FOR CML
Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients
Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis
ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy
Bull's-Eyes and Blind Spots: Pre-Clinical Studies with the Allosteric Inhibitor ABL001 in BCR-ABL1 Compound Mutation-Based Resistance
Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients
Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study
Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission
Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase
Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience
Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia
Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial
Inecalcitol, a Novel Adjuvant Therapy Inhibiting Chronic Myeloid Leukemia (CML) Stem Cells, Activates a Macrophage Differentiation Pathway in Leukemic Progenitors
The Long Non-Coding RNA NEAT1 Modulates Imatinib-Induced Apoptosis in CML Cells
Pulmonary Complications in Patients Treated with Tyrosine Kinase Inhibitors, a Systematic Review and Meta-Analysis
Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias
Switching to Nilotinib Are Associated with Deeper Molecular Responses in Chronic Myeloid Leukemia with Persistent Residual Disease on Long-Term Imatinib Therapy: STAT1 Trial in Japan
Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?
Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study
Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study
Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib
Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients
Velocity of Early BCR-ABL Transcript Elimination As an Optimized Predictor of Deep Molecular Response in Chronic Myeloid Leukemia Patients in Chronic Phase on Treatment with Dasatinib
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib
Interim Analysis of a Multicenter, Prospective Study for Pediatric Chronic Myeloid Leukemia in Chronic Phase: The JPLSG CML-08 Study
Description and Management of Accelerated Phase and Blast Crisis in 21 CML Pediatric Patients
